{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:06:19Z","timestamp":1779174379635,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jaad.2018.03.040","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T23:26:23Z","timestamp":1522538783000},"page":"287-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials"],"prefix":"10.1016","volume":"79","author":[{"given":"Linda Stein","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishnan","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tage","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2018.03.040_bib1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaad.2008.12.032","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies","volume":"60","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.03.040_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/09546634.2013.844314","article-title":"Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression","volume":"25","author":"Levin","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"10.1016\/j.jaad.2018.03.040_bib3","first-page":"945","article-title":"Adrenal suppression with chronic topical corticosteroid use in psoriasis patients","volume":"15","author":"Lam","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.03.040_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1067\/mjd.2003.103","article-title":"Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks","volume":"48","author":"Weinstein","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"5 pt 1","key":"10.1016\/j.jaad.2018.03.040_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0190-9622(98)70594-8","article-title":"Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis","volume":"38","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.03.040_bib6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-4362.2001.01167.x","article-title":"Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs mometasone furoate cream b.i.d. in the treatment of plaque psoriasis","volume":"40","author":"Koo","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.040_bib7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0190-9622(98)70008-8","article-title":"Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.040_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-4362.2001.01234.x","article-title":"A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy","volume":"40","author":"Kaidbey","year":"2001","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.03.040_bib9","first-page":"15","article-title":"Advances in topical delivery systems in acne: new solutions to address concentration dependent irritation and dryness","volume":"9","author":"Ceilley","year":"2011","journal-title":"Skinmed"},{"issue":"3","key":"10.1016\/j.jaad.2018.03.040_bib10","first-page":"194","article-title":"A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol\/tazarotene fixed combination in the treatment of plaque psoriasis","volume":"16","author":"Sugarman","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.03.040_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1087-0024.2004.09113.x","article-title":"10 years experience of the Dermatology Life Quality Index (DLQI)","volume":"9","author":"Lewis","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2018.03.040_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1365-4362.2001.01067-7.x","article-title":"Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments","volume":"40","author":"Lebwohl","year":"2001","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.03.040_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0190-9622(99)70406-8","article-title":"Duration of remission of psoriasis therapies","volume":"41","author":"Koo","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.040_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0190-9622(97)70216-0","article-title":"Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect","volume":"37","author":"Weinstein","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.03.040_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/09546634.2016.1255307","article-title":"Topical corticosteroid concerns from the clinicians' perspective","volume":"28","author":"Mueller","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.jaad.2018.03.040_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-2133.2000.03473.x","article-title":"Topical corticosteroid phobia in patients with atopic dermatitis","volume":"142","author":"Charman","year":"2000","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218304948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218304948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:46:52Z","timestamp":1759272412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218304948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0190962218304948"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.040","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}